21 results about "Hemagglutinin" patented technology

This application discloses a recombinant hemagglutinin protein, its uses, expression methods, and subunit vaccines, belonging to the field of biomedical technology. The technical solution is as follows: a recombinant hemagglutinin protein, obtained by removing the transmembrane and intracellular regions of the HA protein sequence of the H7N9-235 strain and fusing a T4-foldon sequence at the C-terminus; or by retaining the full-length sequence of the HA protein of the H7N9-235 strain. The amino acid sequence of the recombinant hemagglutinin protein is shown in SEQ ID NO.1 or SEQ ID NO.2. The application also discloses a recombinant hemagglutinin protein with good immunogenicity and medical prospects based on the H7N9 strain. Furthermore, when a subunit vaccine is prepared using the recombinant hemagglutinin protein with the transmembrane and intracellular regions removed, the immunogenicity after secondary immunization is significantly enhanced.

This invention discloses a targeted adjuvant influenza vaccine composition for atrial fibrillation patients with atrial fibrosis. The vaccine antigen components are selected from the surface antigens of currently prevalent influenza virus strains, such as hemagglutinin (HA) and neuraminidase (NA). High-purity influenza virus antigens are prepared through cell culture or recombinant DNA technology. For example, influenza virus is cultured using Madin-Darby canine kidney (MDCK) cells, and purified through centrifugation, filtration, and chromatography to obtain high-purity HA and NA antigens. After injection into the human body, the influenza virus antigens (HA and NA) are taken up and processed by antigen-presenting cells (such as macrophages and dendritic cells). The antigen-presenting cells present antigen peptides to T lymphocytes and B lymphocytes, activating a specific immune response. B lymphocytes differentiate into plasma cells with the help of T lymphocytes, producing specific antibodies that recognize and bind to the influenza virus, preventing it from infecting host cells and thus preventing influenza virus infection.

The present invention relates, in particular, to an immunogenic composition for use in the treatment or prevention of infection by influenza virus. The immunogenic composition comprises (a) a first nucleic acid encoding the hemagglutinin (HA) antigen of a strain of a first subtype of influenza A virus, (b) a second nucleic acid encoding the HA antigen of a strain of a second subtype of influenza A virus, (c) a third nucleic acid encoding the HA antigen of a first strain of influenza B virus, and (d) a fourth nucleic acid, optionally included, encoding the HA antigen of a second strain of influenza B virus, wherein the immune response is induced against the aforementioned strains of the first and second subtypes of influenza A virus, the aforementioned first strain and optionally included second strain of influenza B virus, and the HA antigen of at least one further HA antigen subtype of influenza A virus (different from any of the HA antigen subtypes of influenza A virus encoded by the nucleic acids present in the composition). [No selection diagram available]

Provided herein are nucleoside-modified ribonucleic acid molecules encoding a chimeric influenza virus hemagglutinin (HA) polypeptide that comprises a HA globular head domain and a HA stalk domain, wherein the HA stalk domain comprises an amino acid sequence of a HA stalk domain of an influenza B, the HA globular head domain comprises an amino acid sequence of a HA globular head domain of an influenza A, or the HA globular head domain comprises an amino acid sequence of a HA globular head domain of the influenza B, wherein one or more antigenic sites have been replaced with antigenic sites of an influenza A, and the nucleoside-modified RNA molecule comprises at least one pseudouridine. Also provided herein are methods of immunizing a subject against influenza virus disease and methods of preventing influenza virus symptoms in a subject using a composition described herein.

The present invention belongs to the technical field of biomedicine, and specifically relates to a recombinant influenza virus protein, a vaccine, and a preparation method therefor and the use thereof. To overcome the defects of existing influenza vaccines with respect to safety and high toxic side effects, a recombinant influenza virus protein is provided, which has an amino acid sequence as shown in at least one of SEQ ID No. 1 to SEQ ID No. 6. Recombinant hemagglutinin proteins of H1N1 and H3N2 subtypes, and Victoria and Yamagata lineages are expressed and purified by means of an insect baculovirus expression system, and are mixed with an adjuvant to prepare a highly immunogenic recombinant bivalent, trivalent or quadrivalent recombinant influenza virus protein vaccine. The prepared vaccine can induce high levels of specific IgG antibodies and hemagglutination-inhibiting neutralizing antibodies, the addition of adjuvant WGa01 improves the immunogenicity of the vaccine, and the provided vaccine is suitable for people allergic to eggs and has high safety.

This invention discloses the application of a Bag6-overexpressing CHO cell line in the preparation of enhanced exogenous recombinant protein expression levels, belonging to the field of bioengineering technology. The innovation of this invention lies in the significant enhancement of exogenous recombinant protein expression in modified cells obtained by overexpressing Bag6 protein intracellularly. The Bag6-overexpressing CHO cell line in this application technology is constructed by infecting CHO cells with lentivirus to overexpress the Bag6 gene, creating a stable overexpressing Bag6 cell line. Using these stable overexpressing Bag6 cells to express exogenous recombinant proteins (antibodies, hemagglutinin, enzymes, green fluorescent protein, etc.) can significantly increase the yield (1-10 times).

This invention belongs to the field of biomedical technology, specifically relating to a dissociation solution for aluminum adjuvant-adsorbed influenza vaccines and a method for determining antigen content. The dissociation solution of this invention is composed of potassium phosphate solution, diethanolamine, Triton X-100, Tween-20, dodecyl dimethyl betaine, and water. This dissociation solution exhibits excellent dissociation efficiency, achieving a recovery rate of 106%-110% for hemagglutinin from H1N1, H3N2, and BV influenza vaccines. It effectively protects antigen activity and is simple to operate with wide applicability. The dissociated sample can be directly used for mainstream detection methods such as one-way immunodiffusion assay, enzyme-linked immunosorbent assay, and high-performance liquid chromatography, enabling precise quantification of antigen content in aluminum adjuvant-adsorbed influenza vaccines and providing reliable technical support for vaccine quality control.

This invention provides a modified hemagglutinin (HA) protein for preparing a broad-spectrum vaccine against H9 avian influenza, a broad-spectrum vaccine based on the HA protein, a preparation method, and applications. The modified HA protein is obtained through the following strategy: consensus sequences are constructed as immunogenic backbones for the HA sequences of H9 avian influenza viruses at different epidemic periods; based on this, two types of functional mutations are directionally introduced: one type involves transplanting key epitope residues targeted by known broad-spectrum antibodies, and the other type involves neutralizing epitope residues predicted based on viral evolutionary patterns. The modified HA protein of this invention can maintain a highly similar overall fold and trimer interface to the wild type, can be efficiently expressed in eukaryotic systems, and can induce high levels of neutralizing antibodies with broad-spectrum cross-protective effects in target animals. It provides a core antigen candidate for the development of a new generation of H9 broad-spectrum vaccines and has broad application prospects.

The application belongs to the technical field of immunological detection and diagnosis, and particularly relates to an antibody against hemagglutinin of influenza A H1N1 virus and application thereof. The amino acid sequence of CDR1 in the light chain variable region of the antibody is "DHINNW", the amino acid sequence of CDR2 is "GAT", and the amino acid sequence of CDR3 is "QQYWSTPFT"; the amino acid sequence of CDR1 in the heavy chain variable region is "GFSLANYG", the amino acid sequence of CDR2 is "VWAAGDT", and the amino acid sequence of CDR3 is "AKTGTRGGYFDV". The antibody has high recognition specificity, sensitivity and binding affinity to hemagglutinin of influenza A H1N1 virus, can effectively improve the specificity, reliability, accuracy and detection precision of immunological detection of influenza A H1N1 virus, and has an important role in diagnosis and treatment of influenza virus infection.

FIELD: biotechnology.SUBSTANCE: plasmid DNA matrix pVAX-C3-H1-PolyA and the polynucleotide mRNA vaccine synthesized using the said DNA matrix pVAX-C3-H1-PolyA, encoding the hemagglutinin of the influenza A / H1N1 virus and ensuring its expression and induction of a specific immune response when introduced into the body of mammals, used in immunology, genetic engineering, biotechnology and medicine. A recombinant plasmid DNA matrix pVAX-C3-H1-PolyA was obtained, providing expression of mRNA in mammalian cells, having the nucleotide sequence SEQ ID NO: 1 with a size of 4849 bp, a molecular weight of 3.1 MDa and including a fragment of 1680 bp, having coordinates from 699 to 2378 bp and containing an artificial gene encoding the hemagglutinin protein of the influenza A / Wisconsin / 67 / 2022 (H1N1)pdm09 virus without the transmembrane and cytoplasmic domain with the addition of the trimerizing domain of phage T4 with the initiation codon ATG. An mRNA vaccine was obtained having the nucleotide sequence SEQ ID NO: 2, obtained using a DNA matrix and containing an open reading frame encoding the amino acid sequence SEQ ID NO:3 of the influenza virus hemagglutinin immunogen protein, and ensuring the synthesis and secretion of the said protein in the body of mammals.EFFECT: expansion of the range of more relevant mRNA vaccines against the influenza virus.2 cl, 6 dwg, 3 ex

The present invention relates to compositions and methods for inducing an immune response against influenza virus in a subject. In some embodiments, the present invention provides a composition comprising a nucleoside-modified nucleic acid molecule encoding at least one influenza virus antigen, such as a hemagglutinin antigen or a fragment thereof, neuraminidase antigen or a fragment thereof, nucleoprotein antigen or a fragment thereof, matrix protein 1 antigen or a fragment thereof, or matrix-2 ion channel antigen or a fragment thereof.

The application discloses a neutralizing nanobody targeting influenza A virus hemagglutinin and application thereof. The nanobody comprises an amino acid sequence shown as SEQ ID No. 1, and the specificity is jointly determined by three complementarity determining regions (CDRs), namely CDR1 located at positions 26-33, CDR2 located at positions 51-57 and CDR3 located at positions 96-115. The nanobody with high affinity and high specificity is successfully obtained through multiple rounds of panning by phage display library technology. On the basis, a bivalent nanobody with stronger virus neutralization activity and an Fc fusion protein are further developed. Experiments show that the nanobody and the derived antibody provided by the application have excellent influenza A virus neutralization capacity, high solubility, good stability and easy large-scale production characteristics. These advantages make the nanobody and the derived antibody have great application potential and commercial value in the fields of prevention, treatment and clinical diagnosis development of influenza A virus.

The present invention relates to an immunogenic composition comprising first and second RNA replicon particles. The first RNA replicon particle comprises a nucleic acid construct comprising first and second nucleic acid sequences encoding first and second hemagglutinin (HA) antigens of a Swine influenza A virus (IAV-S). The first HA antigen is a of the A / swine / Gent / 1 / 1984-like H3N2 (Gent / 84) lineage, and the second HA antigen is of the A(H1N1)pdm09 (pdm09) lineage. The second RNA replicon particle comprises a nucleic acid construct comprising third and fourth nucleic acid sequences encoding third and fourth HA antigens of S. The third HA antigen is of the A / swine / Scotland / 410440 / 1994-like H1huN2 (Scot / 94) lineage, and the fourth HA antigen is of the Eurasian avian-like H1avN1 (EA) lineage. In other embodiments, the present invention relates to a vaccine, which may be used against influenza A virus infection, and comprising the immunogenic composition. Further provided are methods of making the vaccine and use of the vaccine.

Provided herein are isolated mutant influenza hemagglutinin polypeptides, methods for providing isolated mutant influenza hemagglutinin polypeptides, methods of use of the isolated mutant influenza hemagglutinin polypeptides as a diagnostic or for the isolation of antibodies, compositions comprising the same, vaccines comprising the same and methods of their use, in particular in the detection, prevention and / or treatment of influenza.

Provided herein are monoclonal antibodies or antigen-binding fragments thereof that bind to an influenza B hemagglutinin (HA) protein, pharmaceutical compositions comprising the antibodies, and methods of use. The antibodies can be used to inhibit or neutralize the activity of an influenza B virus, thereby providing a method of treating or preventing an influenza infection in a human. Also provided is the use of one or more antibodies that bind to the influenza B HA for preventing viral adsorption and / or entry into a host cell. The antibodies can be used prophylactically or therapeutically, and can be used alone or in combination with one or more other antiviral agents or vaccines.

This disclosure relates to the field of RNA to prevent or treat multiple infectious agents. In particular, the present disclosure relates to methods and agents for vaccination against coronavirus infection, influenza infection, and / or RSV infection and inducing effective coronavirus, influenza virus, and / or RSV antigen-specific immune responses such as antibody and / or T cell responses. Specifically, in one embodiment, the present disclosure relates to methods comprising administering to a subject (i) a bivalent RNA vaccine encoding peptides or proteins comprising epitopes of SARS-CoV-2 spike proteins (S proteins) and (ii) a tetravalent RNA vaccine encoding peptides or proteins comprising epitopes of hemagglutinin (HA), for inducing an immune response against coronavirus S proteins, in particular S proteins of SARS-CoV-2, and influenza proteins, in particular HA proteins of type A and type B influenza viruses, in the subject.

Immunogenic compositions comprising hemagglutinin (HA) variants and / or neuraminidase (NA) variants, which may be contained in an influenza A virus, and uses thereof for eliciting immune responses against influenza A virus.

The application relates to a purification method of chicken embryo culture influenza virus, and belongs to the technical field of biological medicine. The method is specific capture of inactivated virus liquid from chicken embryos through microspheres; the microspheres swell and adsorb viruses at low temperature, the network structure of the microspheres is triggered to shrink through temperature control, complete virus particles are released, and damage caused by chemical competition elution is avoided; the released viruses are lysed, and then purified through sucrose density gradient centrifugation and molecular sieve chromatography. Through the synergistic effect of impurity removal and specific capture and mild release, the application reduces ovalbumin residues, maintains virus hemagglutinin, and provides an industrialized feasible path for preparation of high-purity and high-immunogenicity influenza vaccine antigen.

The present disclosure provides multivalent influenza vaccine compositions comprising at least three messenger RNAs (mRNAs) encoding a combination of influenza A and influenza B hemagglutinin (HA) antigens, wherein the mRNA encoding the HA antigen of the influenza A virus is present in a different ratio (w / w) than the mRNA encoding the influenza B virus, and methods of eliciting an immune response by administering said compositions. In particular, the disclosures relate to mRNA encoding these antigens formulated in a lipid nanoparticle (LNP).

The present invention provides compositions comprising (a) a combination of influenza viral particles comprising a wild-type hemagglutinin (HA) protein and influenza viral particles comprising a headless HA protein, or (b) a combination of RNA molecules encoding a wild-type HA protein and RNA molecules encoding a headless HA protein. Vaccine formulations comprising these compositions and methods of using these compositions to induce an immune response in a subject are also provided.